Gland Pharma Limited (NSE:GLAND)
India
· Delayed Price · Currency is INR 1,677.50
+8.50 (0.51%)
At close: Mar 9, 2026
Gland Pharma Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 6, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2017 |
| Market Capitalization | 276,379 | 262,358 | 303,932 | 208,882 | 537,705 | 405,432 | Upgrade
|
| Market Cap Growth | 14.95% | -13.68% | 45.50% | -61.15% | 32.63% | - | Upgrade
|
| Enterprise Value | 247,383 | 236,321 | 286,055 | 175,977 | 508,469 | 390,204 | Upgrade
|
| Last Close Price | 1677.50 | 1577.70 | 1809.55 | 1243.71 | 3209.33 | 2430.35 | Upgrade
|
| PE Ratio | 32.62 | 37.56 | 39.35 | 26.74 | 44.38 | 40.67 | Upgrade
|
| Forward PE | 25.90 | 27.55 | 29.26 | 17.57 | 35.96 | 34.98 | Upgrade
|
| PS Ratio | 4.52 | 4.67 | 5.37 | 5.76 | 12.22 | 11.71 | Upgrade
|
| PB Ratio | 2.89 | 2.87 | 3.48 | 2.63 | 7.51 | 6.87 | Upgrade
|
| P/TBV Ratio | 3.01 | 2.98 | 3.63 | 2.63 | 7.53 | 6.87 | Upgrade
|
| P/FCF Ratio | - | 49.48 | 50.08 | 146.03 | 192.42 | 107.78 | Upgrade
|
| P/OCF Ratio | - | 28.68 | 30.49 | 57.39 | 68.00 | 67.02 | Upgrade
|
| PEG Ratio | 0.89 | 1.60 | 1.58 | 1.59 | 1.44 | 1.53 | Upgrade
|
| EV/Sales Ratio | 4.05 | 4.21 | 5.05 | 4.86 | 11.55 | 11.27 | Upgrade
|
| EV/EBITDA Ratio | 17.21 | 19.19 | 22.06 | 17.07 | 33.67 | 29.97 | Upgrade
|
| EV/EBIT Ratio | 23.92 | 27.10 | 29.45 | 19.90 | 36.32 | 32.42 | Upgrade
|
| EV/FCF Ratio | - | 44.57 | 47.14 | 123.03 | 181.96 | 103.74 | Upgrade
|
| Debt / Equity Ratio | 0.03 | 0.03 | 0.04 | 0.00 | 0.00 | 0.00 | Upgrade
|
| Debt / EBITDA Ratio | 0.21 | 0.25 | 0.28 | 0.00 | 0.00 | 0.00 | Upgrade
|
| Debt / FCF Ratio | - | 0.59 | 0.61 | 0.03 | 0.02 | 0.01 | Upgrade
|
| Net Debt / Equity Ratio | -0.30 | -0.29 | -0.18 | -0.47 | -0.45 | -0.51 | Upgrade
|
| Net Debt / EBITDA Ratio | -2.04 | -2.14 | -1.21 | -3.64 | -2.15 | -2.30 | Upgrade
|
| Net Debt / FCF Ratio | - | -4.98 | -2.58 | -26.27 | -11.60 | -7.97 | Upgrade
|
| Asset Turnover | - | 0.51 | 0.58 | 0.44 | 0.61 | 0.65 | Upgrade
|
| Inventory Turnover | - | 1.44 | 1.40 | 1.16 | 1.79 | 1.56 | Upgrade
|
| Quick Ratio | - | 3.01 | 2.61 | 6.58 | 7.80 | 7.31 | Upgrade
|
| Current Ratio | - | 4.34 | 4.04 | 9.46 | 10.06 | 10.00 | Upgrade
|
| Return on Equity (ROE) | - | 7.82% | 9.26% | 10.33% | 18.55% | 20.88% | Upgrade
|
| Return on Assets (ROA) | - | 4.98% | 6.25% | 6.65% | 12.21% | 14.22% | Upgrade
|
| Return on Invested Capital (ROIC) | 10.55% | 8.39% | 11.67% | 16.14% | 30.73% | 34.27% | Upgrade
|
| Return on Capital Employed (ROCE) | - | 9.00% | 10.50% | 11.00% | 19.30% | 20.10% | Upgrade
|
| Earnings Yield | 3.07% | 2.66% | 2.54% | 3.74% | 2.25% | 2.46% | Upgrade
|
| FCF Yield | - | 2.02% | 2.00% | 0.69% | 0.52% | 0.93% | Upgrade
|
| Dividend Yield | 1.08% | 1.14% | 1.10% | - | - | - | Upgrade
|
| Payout Ratio | - | 47.17% | - | - | - | - | Upgrade
|
| Buyback Yield / Dilution | -0.02% | -0.01% | -0.03% | -0.09% | -3.96% | -2.15% | Upgrade
|
| Total Shareholder Return | 1.06% | 1.13% | 1.07% | -0.09% | -3.96% | -2.15% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.